Literature DB >> 27349944

The effect of erythropoietin on cognition in affective disorders - Associations with baseline deficits and change in subjective cognitive complaints.

Caroline Vintergaard Ott1, Maj Vinberg2, Lars V Kessing3, Kamilla W Miskowiak4.   

Abstract

This is a secondary data analysis from our erythropoietin (EPO) trials. We examine (I) whether EPO improves speed of complex cognitive processing across bipolar and unipolar disorder, (II) if objective and subjective baseline cognitive impairment increases patients׳ chances of treatment-efficacy and (III) if cognitive improvement correlates with better subjective cognitive function, quality of life and socio-occupational capacity. Patients with unipolar or bipolar disorder were randomized to eight weekly EPO (N=40) or saline (N=39) infusions. Cognition, mood, quality of life and socio-occupational capacity were assessed at baseline (week 1), after treatment completion (week 9) and at follow-up (week 14). We used repeated measures analysis of covariance to investigate the effect of EPO on speed of complex cognitive processing. With logistic regression, we examined whether baseline cognitive impairment predicted treatment-efficacy. Pearson correlations were used to assess associations between objective and subjective cognition, quality of life and socio-occupational capacity. EPO improved speed of complex cognitive processing across affective disorders at weeks 9 and 14 (p≤0.05). In EPO-treated patients, baseline cognitive impairment increased the odds of treatment-efficacy on cognition at weeks 9 and 14 by a factor 9.7 (95% CI:1.2-81.1) and 9.9 (95% CI:1.1-88.4), respectively (p≤0.04). Subjective cognitive complaints did not affect chances of treatment-efficacy (p≥0.45). EPO-associated cognitive improvement correlated with reduced cognitive complaints but not with quality of life or socio-occupational function. As the analyses were performed post-hoc, findings are only hypothesis-generating. In conclusion, pro-cognitive effects of EPO occurred across affective disorders. Neuropsychological screening for cognitive dysfunction may be warranted in future cognition trials.
Copyright © 2016 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Cognitive impairments; Depressive disorder; Epoetin Alfa; Screening

Mesh:

Substances:

Year:  2016        PMID: 27349944     DOI: 10.1016/j.euroneuro.2016.05.009

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  12 in total

1.  Impact of pretreatment interhemispheric hippocampal asymmetry on improvement in verbal learning following erythropoietin treatment in mood disorders: a randomized controlled trial

Authors:  Kamilla W. Miskowiak; Julie L. Forman; Maj Vinberg; Hartwig R. Siebner; Lars V. Kessing; Julian Macoveanu
Journal:  J Psychiatry Neurosci       Date:  2020-05-01       Impact factor: 6.186

2.  In pursuit of full recovery in major depressive disorder.

Authors:  Vicent-Gil M; Serra-Blasco M; Navarra-Ventura G; Trujols J; Balanzá-Martínez V; Portella Mj; Cardoner N
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-09-09       Impact factor: 5.760

Review 3.  Iron, neuro-bioavailability and depression.

Authors:  Christian Berthou; Jean Paul Iliou; Denis Barba
Journal:  EJHaem       Date:  2021-12-05

4.  Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial.

Authors:  Lejla Sjanic Schmidt; Jeff Zarp Petersen; Maj Vinberg; Ida Hageman; Niels Vidiendal Olsen; Lars Vedel Kessing; Martin Balslev Jørgensen; Kamilla Woznica Miskowiak
Journal:  Trials       Date:  2018-04-19       Impact factor: 2.279

5.  Neural and Behavioral Predictors of Treatment Efficacy on Mood Symptoms and Cognition in Mood Disorders: A Systematic Review.

Authors:  Ida Seeberg; Hanne L Kjaerstad; Kamilla W Miskowiak
Journal:  Front Psychiatry       Date:  2018-07-26       Impact factor: 4.157

6.  Clinical and methodological considerations for psychological treatment of cognitive impairment in major depressive disorder.

Authors:  Katie M Douglas; Melissa Milanovic; Richard J Porter; Christopher R Bowie
Journal:  BJPsych Open       Date:  2020-06-29

7.  Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial.

Authors:  Jeff Zarp Petersen; Lejla Sjanic Schmidt; Maj Vinberg; Martin Balslev Jørgensen; Ida Hageman; Hannelore Ehrenreich; Gitte Moos Knudsen; Lars Vedel Kessing; Kamilla Woznica Miskowiak
Journal:  Trials       Date:  2018-11-06       Impact factor: 2.279

8.  Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Authors:  K W Miskowiak; K E Burdick; A Martinez-Aran; C M Bonnin; C R Bowie; A F Carvalho; P Gallagher; B Lafer; C López-Jaramillo; T Sumiyoshi; R S McIntyre; A Schaffer; R J Porter; I J Torres; L N Yatham; A H Young; L V Kessing; E Vieta
Journal:  Bipolar Disord       Date:  2017-09-12       Impact factor: 6.744

9.  Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial.

Authors:  Caroline V Ott; Maj Vinberg; Christopher R Bowie; Ellen Margrethe Christensen; Gitte M Knudsen; Lars V Kessing; Kamilla W Miskowiak
Journal:  Trials       Date:  2018-09-12       Impact factor: 2.279

10.  Baseline predictors of cognitive change in the treatment of major depressive episode: systematic review.

Authors:  Zoe A Barczyk; Katie M Douglas; Richard J Porter
Journal:  BJPsych Open       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.